Table I.
Patient characteristics according to the primary involved site.
| Characteristics | GI tract | CNS | Breast | Adrenal gland | FGS | Thyroid gland | Bone |
|---|---|---|---|---|---|---|---|
| Total | 42 | 38 | 19 | 15 | 12 | 8 | 7 |
| Age, years | |||||||
| Median | 56 | 58 | 53 | 62 | 59 | 61 | 56 |
| Range | 15–77 | 17–78 | 20–77 | 43–73 | 20–77 | 54–77 | 12–68 |
| Age >60 years | 17 | 14 | 3 | 9 | 5 | 4 | 2 |
| Sex | |||||||
| Male | 28 | 27 | 0 | 8 | 0 | 2 | 6 |
| Female | 14 | 11 | 19 | 7 | 12 | 6 | 1 |
| B symptoms | 24 | 4 | 2 | 7 | 3 | 0 | 5 |
| Increased serum lactate dehydrogenase | 18 | 13 | 3 | 10 | 4 | 4 | 3 |
| ECOG performance status >1 | 13 | 22 | 1 | 7 | 0 | 4 | 3 |
| Ann Arbor stage | |||||||
| I + II | 25 | 34 | 10 | 3 | 6 | 8 | 1 |
| III + IV | 17 | 4 | 9 | 12 | 6 | 0 | 6 |
| Lugano stage | |||||||
| I–IIE | 33 | – | – | – | – | – | – |
| IV | 9 | – | – | – | – | – | – |
| International prognostic index | |||||||
| Low | 12 | 8 | 11 | 0 | 6 | 3 | 2 |
| Low-intermediate | 8 | 14 | 4 | 4 | 1 | 1 | 2 |
| High-intermediate | 11 | 5 | 4 | 2 | 5 | 1 | 2 |
| High | 11 | 11 | 0 | 9 | 0 | 3 | 1 |
| Bone marrow involvement | 2 | 0 | 2 | 1 | 1 | 0 | 1 |
| Hans classification | |||||||
| GCB | 9 | 3 | 5 | 0 | 2 | 3 | 1 |
| Non-GCB | 11 | 14 | 6 | 5 | 3 | 2 | 3 |
| Treatment | |||||||
| Chemotherapy without rituximab | 7 | 22 | 7 | 4 | 6 | 0 | 3 |
| Chemotherapy with rituximab | 35 | 17 | 12 | 9 | 6 | 8 | 4 |
| Chemotherapy with surgery | 23 | 5 | 5 | 0 | 8 | 4 | 0 |
| Risk of CNS relapsea | |||||||
| Low | 12 | – | 11 | 0 | 7 | 3 | 2 |
| Moderate | 18 | – | 8 | 4 | 0 | 2 | 3 |
| High | 12 | – | 0 | 11 | 5 | 3 | 2 |
| CNS prophylaxis | |||||||
| Intrathecal injection | 19 | – | 1 | 5 | 3 | 4 | 4 |
| Intravenous injection of methotrexate | 8 | – | 5 | 5 | 0 | 0 | 1 |
| Combined prophylaxis | 3 | – | 5 | 2 | 2 | 1 | 0 |
| Median follow-up time, months | 36 (1–108) | 29 (1–116) | 22 (3–60) | 14 (1–94) | 13 (6–84) | 24 (16–51) | 16 (9–20) |
| Loss to follow-up | 0 | 7 | 5 | 0 | 1 | 0 | 3 |
a
Risk of CNS relapse was based on the National Comprehensive Cancer Network guidelines. GI, gastrointestinal; CNS, central nervous system; FGS, female genital system; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell.